Literature DB >> 22342985

Defining "epileptogenesis" and identifying "antiepileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as simple as it might seem.

Robert S Sloviter1, Argyle V Bumanglag.   

Abstract

The "latent period" between brain injury and clinical epilepsy is widely regarded to be a seizure-free, pre-epileptic state during which a time-consuming cascade of molecular events and structural changes gradually mediates the process of "epileptogenesis." The concept of the "latent period" as the duration of "epileptogenesis" implies that epilepsy is not an immediate result of brain injury, and that anti-epileptogenic strategies need to target delayed secondary mechanisms that develop sometime after an initial injury. However, depth recordings made directly from the dentate granule cell layers in awake rats after convulsive status epilepticus-induced injury have now shown that whenever perforant pathway stimulation-induced status epilepticus produces extensive hilar neuron loss and entorhinal cortical injury, hyperexcitable granule cells immediately generate spontaneous epileptiform discharges and focal or generalized behavioral seizures. This indicates that hippocampal injury caused by convulsive status epilepticus is immediately epileptogenic and that hippocampal epileptogenesis requires no delayed secondary mechanism. When latent periods do exist after injury, we hypothesize that less extensive cell loss causes an extended period during which initially subclinical focal seizures gradually increase in duration to produce the first clinical seizure. Thus, the "latent period" is suggested to be a state of "epileptic maturation," rather than a prolonged period of "epileptogenesis," and therefore the antiepileptogenic therapeutic window may only remain open during the first week after injury, when some delayed cell death may still be preventable. Following the perhaps unavoidable development of the first focal seizures ("epileptogenesis"), the most fruitful therapeutic strategy may be to interrupt the process of "epileptic maturation," thereby keeping focal seizures focal. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342985      PMCID: PMC3398197          DOI: 10.1016/j.neuropharm.2012.01.022

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  88 in total

1.  Neural networks in human epilepsy: evidence of and implications for treatment.

Authors:  Susan S Spencer
Journal:  Epilepsia       Date:  2002-03       Impact factor: 5.864

2.  Lack of Fos-like immunoreactivity after spontaneous seizures or reinduction of status epilepticus by pilocarpine in rats.

Authors:  L E Mello; C M Kohman; A M Tan; E A Cavalheiro; D M Finch
Journal:  Neurosci Lett       Date:  1996-04-19       Impact factor: 3.046

3.  Further evidence that pathologic high-frequency oscillations are bursts of population spikes derived from recordings of identified cells in dentate gyrus.

Authors:  Anatol Bragin; Simone K Benassi; Farshad Kheiri; Jerome Engel
Journal:  Epilepsia       Date:  2011-01-04       Impact factor: 5.864

4.  The use of radiotelemetry to evaluate electrographic seizures in rats with kainate-induced epilepsy.

Authors:  Philip Williams; Andrew White; Damien Ferraro; Suzanne Clark; Kevin Staley; F Edward Dudek
Journal:  J Neurosci Methods       Date:  2006-03-27       Impact factor: 2.390

5.  Stereological analysis of forebrain regions in kainate-treated epileptic rats.

Authors:  Shaoyun Chen; Paul S Buckmaster
Journal:  Brain Res       Date:  2005-09-28       Impact factor: 3.252

Review 6.  Anti-epileptogenesis in rodent post-traumatic epilepsy models.

Authors:  Asla Pitkänen; Tamuna Bolkvadze; Riikka Immonen
Journal:  Neurosci Lett       Date:  2011-03-21       Impact factor: 3.046

7.  Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy.

Authors:  E A van Vliet; S da Costa Araújo; S Redeker; R van Schaik; E Aronica; J A Gorter
Journal:  Brain       Date:  2006-11-22       Impact factor: 13.501

8.  Spontaneous recurrent seizures in rats: an experimental model of partial epilepsy.

Authors:  J P Leite; Z A Bortolotto; E A Cavalheiro
Journal:  Neurosci Biobehav Rev       Date:  1990       Impact factor: 8.989

9.  Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats.

Authors:  Claudia Brandt; Maike Glien; Heidrun Potschka; Holger Volk; Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2003 Jun-Jul       Impact factor: 3.045

10.  Mechanisms of seizure-induced 'transcriptional channelopathy' of hyperpolarization-activated cyclic nucleotide gated (HCN) channels.

Authors:  Cristina Richichi; Amy L Brewster; Roland A Bender; Timothy A Simeone; Qinqin Zha; Hong Z Yin; John H Weiss; Tallie Z Baram
Journal:  Neurobiol Dis       Date:  2007-09-22       Impact factor: 5.996

View more
  27 in total

1.  Evolution of temporal and spectral dynamics of pathologic high-frequency oscillations (pHFOs) during epileptogenesis.

Authors:  Ryan T Jones; Albert M Barth; Laurel D Ormiston; Istvan Mody
Journal:  Epilepsia       Date:  2015-10-30       Impact factor: 5.864

Review 2.  Concise Review: Prospects of Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells for Treating Status Epilepticus and Chronic Epilepsy.

Authors:  Satish Agadi; Ashok K Shetty
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

Review 3.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

Review 4.  Issues related to development of antiepileptogenic therapies.

Authors:  Asla Pitkänen; Astrid Nehlig; Amy R Brooks-Kayal; F Edward Dudek; Daniel Friedman; Aristea S Galanopoulou; Frances E Jensen; Rafal M Kaminski; Jaideep Kapur; Henrik Klitgaard; Wolfgang Löscher; Istvan Mody; Dieter Schmidt
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

5.  Progressive neuronal activation accompanies epileptogenesis caused by hippocampal glutamine synthetase inhibition.

Authors:  Benjamin Albright; Roni Dhaher; Helen Wang; Roa Harb; Tih-Shih W Lee; Hitten Zaveri; Tore Eid
Journal:  Exp Neurol       Date:  2016-10-18       Impact factor: 5.330

6.  Network evolution in mesial temporal lobe epilepsy revealed by diffusion tensor imaging.

Authors:  Helen Wang; Yuegao Huang; Daniel Coman; Reshma Munbodh; Roni Dhaher; Hitten P Zaveri; Fahmeed Hyder; Tore Eid
Journal:  Epilepsia       Date:  2017-04-05       Impact factor: 5.864

Review 7.  Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy.

Authors:  Bryan L Clossen; Doodipala Samba Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-05       Impact factor: 5.187

Review 8.  Prevention of Epilepsy: Issues and Innovations.

Authors:  Dieter Schmidt; Matti Sillanpää
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

Review 9.  Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies.

Authors:  H Steve White; Wolfgang Löscher
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 10.  The Epilepsy Spectrum: Targeting Future Research Challenges.

Authors:  Gregory L Holmes; Jeffrey L Noebels
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.